Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that, pursuant to the news release announced November 21, 2016, Sechelt Organic Marijuana Inc. (“Sechelt”), has been notified by Health Canada that it has successfully progressed into the Final Review stage of the ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) application process. Veritas has been granted the exclusive option to acquire 100% ownership of Sechelt, subject to certain terms and conditions including; obtaining an ACMPR/MMPR license and the issuance of a permit by Health Canada for the building of a cannabis growing facility.
Sechelt currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4th, 2014, and has had an application pending with Health Canada for a new ACMPR license. Sechelt personnel includes an experienced grow master who is currently a ‘designated grower’ under current ACMPR licensing guidelines Health Canada will now assess Sechelt’s physical security plans to validate the information in its application.
“Sechelt sits with a minority of applicants who have successfully moved through the security clearance stage and into the final review stage,” stated Veritas CEO, Dr. Lui Franciosi. “We are excited by the prospect of Sechelt receiving its ACMPR license in due course, which is a significant development for it, Veritas and Cannevert.”
Veritas Pharma and Cannevert Therapeutics have been actively preparing for their first clinical trials of select cannabis strains targeting pain sometime this year. This scientific work forms the basis for Veritas’ future branding and traction in Canadian market, especially if Health Canada issues Sechelt a grower’s license. The Company will be in a better position to produce special varieties of cannabis that have the ideal therapeutic characteristics. Upon Cannevert Therapeutics completing the clinical evidence and Sechelt obtaining a production license, Veritas will be in a strong position to enter the United States with Marapharm Ventures Inc. as its key partner. Marapharm has significant ownership of Veritas.
Veritas would also like to announce that 400,000 stock options have been issued; 200,000 each to two consultants. The options will be vested immediately and have an exercise price of $0.47. The options will expire, if unexercised, in one year from date of issue. Further to the January 12, 2017 announcement of the issuance of warrants expiring on June 7, 2018, the Company has paid a 10% or $50,000 in finders’ fees to unrelated third parties.
About Sechelt Organic Medicine Inc.
Sechelt was formed to become a producer of medical marijuana under the ACMPR license. The products designed by Cannevert Therapeutics require the ability to grow specific strains of medical marijuana under ideal conditions. Sechelt provides Cannevert Therapeutics this ability.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $1,250,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
Click here to learn more about Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP).
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announces it has completed a first closing of a non-brokered private placement of up to $2,000,000. The Company accepted subscriptions for 13,740,000 units at a price of $0.05 per unit, for gross proceeds of $687,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.075 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days
The Company paid $18,000 in cash and issued 160,000 warrants on the same terms as noted above to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until April 5, 2021. The Company is expecting to complete the financing by December 16, 2020. Proceeds will be used for working capital and to fund future investments.
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press release dated December 3, 2020, the TSX Venture Exchange has approved the repricing of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.
For anybody wishing to exercise these Warrants, please contact the Chief Executive Officer, Terry Donnelly at the particulars below.
Cannabis Profits In Focus: CEO’s of HEXO, Icanic Brands, Tilray, and Aurora Cannabis Discuss Next Wave of Global Growth Opportunities and Brands Innovation
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB) (TSX: ACB), and HEXO Corp. (NYSE: HEXO)
Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:
TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.
In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.
Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.
DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.